Study: NCT05081609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TransCon IL-2 β/γ
Description: TransCon IL-2 β/γ will be administered as an intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TransCon IL-2 β/γ
Description: TransCon IL-2 β/γ will be administered as an intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TransCon IL-2 β/γ
Description: TransCon IL-2 β/γ will be administered as an intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TransCon IL-2 β/γ
Description: TransCon IL-2 β/γ will be administered as an intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TransCon IL-2 β/γ
Description: TransCon IL-2 β/γ will be administered as an intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TransCon IL-2 β/γ
Description: TransCon IL-2 β/γ will be administered as an intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TransCon IL-2 β/γ
Description: TransCon IL-2 β/γ will be administered as an intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TransCon IL-2 β/γ
Description: TransCon IL-2 β/γ will be administered as an intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TransCon IL-2 β/γ
Description: TransCon IL-2 β/γ will be administered as an intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered as an intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered as an intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered as an intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered as an intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered as an intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy drug
Description: SOC chemotherapy will be administered as an intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy drug
Description: SOC chemotherapy will be administered as an intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TransCon TLR7/8 Agonist
Description: TransCon TLR7/8 Agonist will be administered as an IT (Intratumoral) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TransCon TLR7/8 Agonist
Description: TransCon TLR7/8 Agonist will be administered as an IT (Intratumoral) injection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery will take place 4-6 weeks after last dose of study treatment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery will take place 4-6 weeks after last dose of study treatment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery will take place 4-6 weeks after last dose of study treatment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery will take place 4-6 weeks after last dose of study treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab will be administered as an intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine (T-DM1)
Description: Trastuzumab emtansine (T-DM1) will be administered as an intravenous (IV) infusion